Adagrasib (Krazati) belongs to several generations of targeted drugs and a summary of its clinical application characteristics

Adagrasiib (Krazati) is a new type of targeted drug mainly used to treat patients with solid tumors carrying KRAS G12C mutations, especially non-small cell lung cancer (NSCLC). As a specific inhibitor of KRAS G12C, it can selectively inhibit the activity of mutant KRAS protein, thereby blocking tumor cell proliferation signals, which is an important development in the field of precision anti-tumor therapy.

Adagrasiib is classified as a new generation (third generation) targeted drug. Compared with the first or second generation targeted drugs, it not only has higher selectivity and targeting, but can also effectively act on KRAS mutant proteins that were previously difficult to target, thus filling the treatment gap that traditional targeted therapies cannot cover. Its design concept is to directly target key mutation sites that drive tumors to improve efficacy while reducing non-specific side effects.

In clinical trials, adagrasib showed good anti-tumor activity and tolerability. It is mainly used for advanced or metastatic KRAS G12C mutation-related solid tumors, which can significantly delay disease progression and improve patients' progression-free survival (PFS). In addition, the drug is easy to take orally and facilitates long-term management of patients' tumor control. It also has little impact on indicators such as weight and blood sugar, making it suitable for use in comprehensive management programs.
Compared with traditional targeted drugs, adagrasib has the advantages of high selectivity, low drug resistance and precision treatment potential. For clinical use, genetic testing is required to screen patients with indications to ensure targeted treatment. At the same time, it can be used as part of individualized treatment in combination chemotherapy or other targeted drug regimens to achieve the best balance of efficacy and safety. Doctors will make decisions based on the patient's tumor type, gene mutation status and past treatment history when making selections.
Reference link: https://www.drugs.com